Skip to main content

Day: August 31, 2022

Azerion publishes Interim Unaudited Q2 and H1 2022 Results

Resilient business model reflected in revenue and gross margin expansion The summary provided below relates to the Q2 and H1 2022 results of Azerion Holding B.V., which is the main operational holding subsidiary of Azerion Group N.V. Highlights of Q2 2022Net Revenue of EUR 104 million, nearly doubling Q2 2021, driven by acquisitions and organic growth. Adjusted EBITDA approaching EUR 12 million, up by 70% compared to Q2 2021, primarily boosted by improved net revenue and gross profit margin. Accelerated the integration of acquisitions, pointing to further synergies and productivity upside; increased focus on operational efficiencies and costs to strengthen our resilience. Partnership with ITV studios, with Love Island opening a virtual villa in Hotel Hideaway. Partnerships with Cyberkongs, Metaverse HQ and Metakey to increase the utility...

Continue reading

Auriant Mining AB (publ.) publishes Q2 2022 Interim Report (January – June)

Highlights Amounts in parentheses refer to the same period in the previous year.Gold production 423.1 kg / 13,605 oz (454.9 kg /14,626 oz). Gold sales 435.5 kg /14,000 oz (391.8 kg /12,598 oz) Consolidated revenue US$ 26.3 mln (US$ 22.9 mln) Net profit after tax US$ 9.7 mln (US$ 3.7 mln) EBITDA US$ 13.5 mln (US$ 10.6 mln) Net cash flow generated from operating activities US$ 7.4 mln (US$ 10.7 mln) Average selling price for gold US$ 1,878 per oz (US$ 1,821 per oz) 2022 updated annual production forecast is 800 kg of gold.Significant events after the reporting period Birgit Köster Hoffmann, member of the Board of directors of Auriant Mining AB (publ.) (the “Company”) resigned from the Company’s Board of directors for personal reasons on 18 August 2022. Birgit Köster Hoffmann joined the Company’s Board of directors in May 2021 and was...

Continue reading

Maxima Group’s Supervisory Board changes its composition

Laimonas Devyžis resigned from the Supervisory Board of Maxima Grupė as of 30 August this year. He is replaced on the Supervisory Board by Nerijus Maknevičius, current CEO of Galio Group. The Supervisory Board of Maxima Grupė is now composed of Mr. N. Maknevičius, Mr. Manfredas Dargužis, Chairman of the Management Board and CEO of Akropolis Group, and Ms. Evelina Černienė, CFO of Vilniaus Prekyba, who chairs the Supervisory Board. The term of office of the Supervisory Board ends in 2026. Additional information Maxima Grupė operates Maxima (Baltic States), Stokrotka (Poland), T-Market (Bulgaria) retail stores and Barbora, an online food store in the Baltic States and Poland. At the end of 2021, the Maxima Group had over 1,400 stores in five countries and revenues of €4.5 billion. The company belongs to the Vilniaus Prekyba group of companies....

Continue reading

Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates

— Clinical trials of core drug candidates are progressing steadily with the debut of the company’s FIH asset — Toripalimab’s sales performance is consistently improving; the US BLA is under review SHANGHAI, China, Aug. 31, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced its 2022 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTSTotal revenue reached approximately RMB 946 million in the first half of 2022. In particular, the sales revenue of TUOYI® (toripalimab) was approximately RMB 298 million, representing an increase of approximately 195% compared to the second half of 2021....

Continue reading

Ackermans & van Haaren realises a record profit of 278.4 million euros over the first half of 2022

Dear shareholder, Dear Madam, Dear Sir,Ackermans & van Haaren realises a record profit of 278.4 million euros over the first half of 2022 thanks to:generally good results in the group’s core segments, which is reflected in a 5% higher profit contribution; a positive evolution of the Growth Capital participations, both within the consolidated participations as well as in the more recent initiatives in India and South-East Asia; the 97.2 million euros capital gain on the sale of Manuchar.After the sale of Anima (closed in July 2022 and therefore not yet included in the result as at June 30), Ackermans & van Haaren has a net cash position of more than 500 million euros.“In a challenging environment with steep cost increases, deteriorating consumer confidence and decreasing stock markets, the companies of the group...

Continue reading

PCI Biotech interim first-half year 2022 results

Oslo (Norway), 31 August 2022 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first-half year 2022 results. Please find enclosed the report and presentation. Highlights Corporate*The previously reported efforts to finance a Ph II clinical trial in head and neck cancer did not, under the current market conditions, result in a feasible way forward and PCI Biotech will not conduct a company-sponsored Ph II trial with the fimaVacc technology *The company will focus its efforts and resources on non-clinical research, developing further the current pipeline opportunities while exploring new fields of use for the PCI technology utilising fimaVacc for intratumoural immunotherapy, and fimaNAc for dermatology and bioprocessing applications fimaVacc – intratumoural immunotherapy*The results from...

Continue reading

IBA Reports Half Year 2022 Results

RECORD ORDER INTAKE AND BACKLOG ACROSS THE GROUP HIGHLY ACTIVE PIPELINE FOR ALL BUSINESS LINES SOLID BALANCE SHEET WITH RECORD EUR 137 MILLION NET CASH Louvain-la-Neuve, Belgium, 31 August 2022 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2022.(EUR 000) H1 2022 H1 2021 Variance Variance % Total Net Sales 160 032 137 183 22 849 16.7%  Proton Therapy 103 026 70 473 32 553 46.2%  Other Accelerators 30 110 40 285 -10 175 -25.3%  Dosimetry 26 896 26 425 471 1.8% REBITDA 14 065 5 745 8 320 144.8%    % of Sales 8.8% 4.2%     REBIT 4 564 674 3 890 577.2%    % of Sales 2.9% 0.5%     Profit Before Tax 297 -843 1 140 135.2%    % of Sales 0.2% -0.6%     NET RESULT -1 717 -1 935 218 11.3%    % of Sales -1.1% -1.4%    Financial...

Continue reading

Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update

Interim data from Phase 2 KINETIC clinical trial of KIN001 to treat hospitalized COVID-19 patients expected in Q3 2022 First patient dosed with in Phase 2 KINFAST clinical trial with ambulatory COVID-19 mild-patients Signed a CHF 20 million financing with Yorkville Advisors Fully financed until Q1 2023Basel, Switzerland, August 31, 2022 – Kinarus Therapeutics Holding AG (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today reported results for the six months ended June 30, 2022, and provided a corporate update. Dr. Alexander Bausch, CEO of Kinarus Therapeutics Holding AG, commented: “We believe we are well positioned to execute on multiple value-creating milestones. As a first of many, our experienced team is working to deliver in Q3 2022 interim...

Continue reading

Avance Gas Holding Ltd: Key information relating to the dividend for the second quarter 2022

Key information relating to the dividend to be paid by Avance Gas Holding Ltd. for the second quarter 2022: Dividend amount: $0.20 Declared currency: USD Last day including right: 6 September 2022 Ex-date: 7 September, 2022 Record date: 8 September, 2022 Payment date: 15 September, 2022 Date of approval: 30 August, 2022 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Continue reading

Avance Gas Holding Ltd: Financial Results for Q2 2022

BERMUDA, August 31 2022 – Avance Gas Holding Ltd (OSE: AGAS) (“Avance Gas” or the “Company”) today reports unaudited results for the second quarter 2022. HIGHLIGHTSThe average time charter equivalent (TCE) rate on load to discharge basis was $36,212/day compared to $37,608/day for the first quarter 2022. This was ahead of guidance of between $32,000/day to $33,000/day.  Daily operating expenses (OPEX) were $8,200/day, down from $8,500/day for the first quarter. Net profit of $18.4 million compared to $24.3 million for the first quarter 2022, or earnings per share of 24 cents compared to 32 cents for the first quarter.  During the second quarter 2022, the Company completed the sale of the 2008-built VLGC Providence with the vessel being delivered to the new owners in May. The sale generated a gain on sale of $4.5 million and a cash release...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.